Hallucinogen in 'magic mushrooms' relieves depression in largest clinical trial to date... - 0 views
-
gilbertpacheco on 20 Nov 21Is it time to pick up some PSYK, PSY and PSIL ETFs? "Given the strong results, Compass Pathways plans to move ahead with a late-stage clinical trial of psilocybin, likely using the 25-milligram dose, but that detail still needs to be discussed with regulators. The recent trial was a so-called Phase 2B trial, which was intended to figure out the appropriate dose; the next trial, a Phase 3, will test that chosen dose in a larger group." Where do we sign up?